136
Participants
Start Date
April 1, 2022
Primary Completion Date
December 1, 2022
Study Completion Date
December 1, 2022
Abemaciclib
Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
Abemaciclib
Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Abemaciclib
Abemaciclib 200 mg orally every 12 hours
Russian Society of Clinical Oncology, Moscow
Russian Society of Clinical Oncology
UNKNOWN
Blokhin's Russian Cancer Research Center
OTHER